ArticleDiscover oncology2025
C20orf27 promotes hepatocellular carcinoma progression via NT5E.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Liver cancer is one of the most lethal human malignancies in the world. Although great efforts have been made to develop novel therapeutic targets, effective drug targeting remains limited. C20orf27, located on human chromosome 20, is a gene whose function has not been fully elucidated. In this study, we identified C20orf27 as a critical gene that facilitates liver cancer progression. We detected that C20orf27 was upregulated in liver cancer samples. Gain- and loss-of-function experiments demonstrated that C20orf27 enhanced liver cancer cell proliferation and migration by regulating cyclin-related proteins, including MDM2, PCNA, Cyclin E1, CDK2, and p-Rb. RNA sequencing and bioinformatics analyses revealed that NT5E, ACE, and TTR were potential downstream targets of C20orf27. Immunohistochemistry analysis of tissue microarrays suggested that NT5E expression was significantly associated with C20orf27 levels. Moreover, the combination of C20orf27 and NT5E predicted the prognosis of liver cancer patients, as higher levels of both were associated with poorer overall survival and disease-free survival after surgery. Our findings are the first to report the functional role of the C20orf27/NT5E axis in promoting hepatocellular carcinoma progression, highlighting its potential as a novel therapeutic target and biomarker for HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.